Company: IMRX
Filing Date: 2025-09-25
Form Type: 424B5
Source: 0001104659-25-093438
Chunk: 14

Company: Immuneering Corp
Filing Date: 2025-09-25
Form: 424B5
Chunk 14
---
 right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any of our Class A common stock or securities convertible into or exercisable or exchangeable for any of our Class A common stock, or enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of our Class A common stock, whether any of these transactions are to be settled by delivery of our Class A common stock or other securities, in cash or otherwise, without, in each case, the prior written consent of Leerink Partners, who may release any of the securities subject to these lock-up agreements at any time without notice. Notwithstanding the above, we may sell shares under our “at-the-market” program 30 days after the date of this prospectus supplement provided that such shares are being sold at a price that is higher than the public offering price in this transaction. Exceptions to the lock-up restrictions are described in more detail in this prospectus supplement under the caption “Underwriting.”

<div align='center'>S-10</div>

TABLE OF CONTENTS

### USE OF PROCEEDS
We estimate that the net proceeds from this offering will be approximately $164.1 million (or approximately $188.7 million if the underwriters exercise their option to purchase additional shares in full) after deducting the underwriting discounts and commissions and estimated offering expenses payable by us.

We estimate that the net proceeds from the concurrent private placement will be $23.3 million after deducting estimated private placement fees payable by us.

We intend to use the net proceeds from this offering and the concurrent private placement to advance the preclinical and clinical development of our product candidates and for working capital and other general corporate purposes.

Based on our current plans, we believe our existing cash and cash equivalents and marketable securities, together with the net proceeds from this offering and the concurrent private placement (and excluding net proceeds from any exercise of the underwriters’ option to purchase additional shares of our common stock), will be sufficient to fund our operating expenses and capital expenditure requirements into 2029. The amounts and timing of our actual expenditures will depend on numerous factors, including the progress of our clinical trials and other development efforts and other factors described under “Risk Factors” in this prospectus supplement, the accompanying base prospectus and the documents incorporated by reference herein and therein, as well as the amount of cash used in our operations. We may find it necessary or advisable to use the net proceeds for other purposes, and